NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

CSCI

COSCIENS Biopharma Inc

Jul 09 • 02:06PM ET

3.54

Dollar change -0.12
Percentage change -3.15	%

Healthcare • Biotechnology • Canada • NASD

Peers: AMGN GILD REGN VRTX BIIB BMY MRNA LLY INCY NBIX

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-5.80	Insider Own	1.48%	Shs Outstand	3.15M	Perf Week	3.97%
Market Cap	11.14M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	3.10M	Perf Month	-4.97%
Enterprise Value	-0.39M	PEG	-	EPS next Q	-	Inst Own	9.04%	Short Float	0.62%	Perf Quarter	20.07%
Income	-17.56M	P/S	1.23	EPS this Y	-	Inst Trans	-26.13%	Short Ratio	5.33	Perf Half Y	24.47%
Sales	9.03M	P/B	1.10	EPS next Y	-	ROA	-55.81%	Short Interest	0.02M	Perf YTD	27.62%
Book/sh	3.22	P/C	0.81	EPS next 5Y	-	ROE	-151.97%	52W High	7.54 -53.12%	Perf Year	-22.48%
Cash/sh	4.37	P/FCF	-	EPS past 3/5Y	6.61% 29.70%	ROIC	-144.95%	52W Low	1.96 80.36%	Perf 3Y	-80.73%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	22.15% 78.30%	Gross Margin	45.86%	Volatility	3.82% 4.51%	Perf 5Y	-96.16%
Dividend TTM	-	EV/Sales	-0.04	EPS Y/Y TTM	80.05%	Oper. Margin	-175.15%	ATR (14)	0.18	Perf 10Y	-99.88%
Dividend Ex-Date	-	Quick Ratio	2.54	Sales Y/Y TTM	280.37%	Profit Margin	-194.50%	RSI (14)	52.91	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.88	EPS Q/Q	93.87%	SMA20	1.61%	Beta	0.89	Target Price	60.00
Payout	-	Debt/Eq	0.22	Sales Q/Q	37400.00%	SMA50	1.20%	Rel Volume	0.65	Prev Close	3.65
Employees	40	LT Debt/Eq	0.19	Earnings	-	SMA200	9.16%	Avg Volume	3.61K	Price	3.54
IPO	May 10, 2000	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	1,687	Change	-3.15%

Jun-30-25 06:33PM	COSCIENS Biopharma Announces Results of Virtual 2025 Meeting of Shareholders (GlobeNewswire)
May-30-25 05:00PM	COSCIENS Biopharma Inc. Reconstitutes Board for Benefit of Shareholders (GlobeNewswire) +8.31%
May-27-25 07:50AM	Cosciens Biopharma announces receipt of Goodwood intended director nominations (TipRanks) -5.92%
May-26-25 06:50AM	COSCIENS Biopharma Inc. Acknowledges Receipt of Intended Director Nominations from Goodwood for the Upcoming Annual and Special Meeting of Shareholders (GlobeNewswire)
May-23-25 04:30PM	Goodwood to Nominate New Directors for COSCIENS Biopharma Inc. (PR Newswire) -5.92%
05:05PM	Loading…
May-13-25 05:05PM	COSCIENS Biopharma Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update (GlobeNewswire)
Apr-14-25 07:00AM	COSCIENS Biopharma Inc. Appoints Global Consumer Products and Biosciences Executive, Anna Biehn as Chief Executive Officer (GlobeNewswire)
Apr-09-25 05:00PM	COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update (GlobeNewswire) +15.10%
Apr-01-25 07:25PM	COSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade Order (GlobeNewswire)
Mar-21-25 07:07AM	Why COSCIENS Biopharma Inc. (CSCI) Went Down On Thursday? (InsiderMonkey) -6.71%
Mar-19-25 07:33PM	COSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting Documents (Newsfile) +30.63% -21.15%
Mar-13-25 07:55AM	COSCIENS Biopharma Inc. Announces Successful Phase 1 Results Supporting Initiation of Phase 2a Clinical Efficacy Trial with Avenanthramides as a Potential Anti-Inflammatory Product (GlobeNewswire) +15.61%
Dec-23-24 07:45AM	COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization (GlobeNewswire)
Nov-12-24 07:30AM	COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs (GlobeNewswire) -10.18%
Oct-08-24 07:30AM	COSCIENS Biopharma Announces Change to Board of Directors (GlobeNewswire)
05:30PM	Loading…
Oct-01-24 05:30PM	COSCIENS Biopharma Announces Appointment of Pierre Labbe as Director (GlobeNewswire)
05:30PM	COSCIENS Biopharma Announces Appointment of Pierre Labb as Director (GlobeNewswire)
Sep-23-24 07:30AM	COSCIENS Biopharma Inc. Provides Updates on Merger Integration, Management Succession Plans and Ongoing Development Programs (GlobeNewswire) -5.58%
Aug-27-24 07:30AM	COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency (GlobeNewswire) -32.42%
Aug-13-24 08:05AM	COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results (GlobeNewswire)

COSCIENS Biopharma Inc. engages in the development and commercialization of diverse pharmaceutical and diagnostic products. It operates through the Active Ingredient and Biopharmaceutical segments. The Active Ingredient segment is involved in the development of proprietary extraction technologies. The Biopharmaceutical segment includes commercializing and developing pharmaceutical therapeutics and diagnostic tests. The company was founded on September 12, 1990 and is headquartered in Toronto, Canada.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CSCI

COSCIENS Biopharma Inc

Upgrade your FINVIZ experience